Overview
Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.
Lobbying Costs
None declared
Financial year: Jan 2022 - Dec 2022
Lobbyists (Full time equivalent)
0.75 Fte (3)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
European Society for Radiotherapy and Oncology (ESTRO)
EU Transparency Register
114144232470-50 First registered on 21 Sep 2018
Goals / Remit
ESTRO, the European SocieTy for Radiotherapy & Oncology, is a scientific non-profit organisation whose mission is to further reinforce radiation oncology as a core partner in multidisciplinary cancer care and to guarantee accessible and high-value radiation therapy for all cancer patients who need it. This is emphasized in ESTRO’s vision statement for 2030 ‘Radiation Oncology. Optimal Health for All, Together’.
ESTRO promotes education, science, research and advocate for access to radiotherapy. Throughout the year, the Society organises an annual Congress, teaching courses, workshops, and public affairs activities and publishes scientific material in its family of journals.
The Society counts over 9,000 members in and outside Europe and supports all the radiation oncology professionals and the wider oncology community in their daily practice.
https://www.estro.org/ESTRO/media/ESTRO/About/190417-ESTRO-Vision-Paper-2030.pdfMain EU files targeted
EU public health policy, Research and Innovation
Europe's Beating Cancer Plan
EU4Health
IHI
EURATOM
SAMIRA action plan
IPAAC Innovative Partnership for Actions Against Cancer https://www.ipaac.eu
JARC Joint Action on Cancer (together with SIOPE https://www.siope.eu/)
ERN European Reference Network http://www.ern-rnd.eu/
IMI Innovative Medicines Agency https://www.imi.europa.eu/
COUNCIL DIRECTIVE 2013/59/EURATOM of 5 December 2013 laying down basic safety standards for protection against the dangers arising from exposure to ionising radiation, and repealing Directives 89/618/Euratom, 90/641/ ARTICLE 63 + 78
Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross-border healthcare
Directive 2013/35/EU of the European Parliament and of the Council of 26 June 2013 on the minimum health and safety requirements regarding the exposure of workers to the risks arising from physical agents (electromagnetic fields)
Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU
Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC
Inputs provided on the ESCO forum, regarding the professions working in radiotherapy
Proposal for a thematic network on EU Health Policy PlatformAddress
Head Office
Avenue Marnix 17
Brussels 1000
BELGIUMEU Office
Avenue Marnix 17
Brussels 1000
BELGIUMWebsite
-
People
Total lobbyists declared
3
Employment time Lobbyists 25% 3 Lobbyists (Full time equivalent)
0.75
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Non-governmental organisations, platforms and networks and similar
-
Networking
Affiliation
European Cancer Organisation
Union for International Cancer Control (UICC)Member organisations
Approx 9000 members, based in apporx 100 countries representing the ESTRO community.
Membership structure: https://www.estro.org/Membership
annual report 2022: https://www.estro.org/ESTRO/media/ESTRO/About/Annual%20report/230525-ESTRO_Annual-Report2022-FINAL-1-JUNE.pdf -
Financial Data
Interests represented
Does not represent commercial interests
Closed financial year
Jan 2022 - Dec 2022
Lobbying costs for closed financial year
Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.
Total organisational budget in closed year
7,101,664€
Major funding types in closed year
Other, Member's contribution
Funding types "other" information
Major contributions in closed year
Type Name Amount Grant INTERACT PROJECT 42,780€ Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
Projects:
- HERO project, Health Economics in Radiation Oncology. https://www.estro.org/about-us/health-economics-in-radiation-oncology---hero/hero
- ROSEIS, Radiation Oncology Safety Education and Information System. https://roseis.estro.org
Projects in collaboration with the ESTRO Cancer Foundation:
- VBHC: https://www.estro.org/Advocacy/ECF/Value-Based-HealthCare-(VBHC)
- UpLung: https://www.estro.org/Advocacy/ECF/UpLung
Communications activities:
- ESTRO Annual report 2022 https://www.estro.org/ESTRO/media/ESTRO/About/Annual%20report/230525-ESTRO_Annual-Report2022-FINAL-1-JUNE.pdf
- ESTRO SYMPOSIUM AT THE EUROPEAN PARLAMENT: "Radiotherapy Cures Cancer Today", organised on the 5th Dec 2017. https://www.estro.org/binaries/content/assets/estro/about/news/event-report-radiotherapy-cures-cancer-today-5th-december-2017.pdf
Publications:
- Kazmierska J, et al. 2019. Radiotherapy: seizing the opportunity in cancer care. Tumori Journal 2019, Vol. 105(2S) 3–59
- Lievens Y, et al. Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol 2014;112:178– 86
- Dunscombe P, et al. Guidelines for equipment and staffing of radiotherapy facilities in the European countries: final results of the ESTRO-HERO survey., Radiother Oncol. 2014 Aug;112(2):165-77
- Borras JM, et al. The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis. Radiother Oncol. 2015 Jul;116(1):38-44
- Borras, J. M., et al. How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis. Radiotherapy and Oncology 2016, 119(1), 5-11.
- Defourny, N., et al. Cost evaluations of radiotherapy: What do we know? An ESTRO-HERO analysis. Radiotherapy and Oncology 2016, 121(3), 468-474.
-Lievens, Yolande; et al; GIRO Steering and Advisory Committees - Global impact of radiotherapy in oncology: Saving one million lives by 2035, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, ISSN: 1879-0887, Vol: 125, Issue: 2, Page: 175-177 Publication Year: 2017
-Coffey M, Technical Innovations & Patient Support in Radiation Oncology. Elsevier BV ISSN: 2405-6324, Vol: 1, Page: 16-17 Publication Year: 2017
- Borras, Josep M; et al, Estimating the number of fractions by tumour site for European countries in 2012 and 2025: An ESTRO-HERO analysis. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology, ISSN: 1879-0887, Vol: 126, Issue: 2, Page: 198-204 Publication Year: 2018
- Lievens Y, at al,Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective. Lancet Oncol. 2019;20(2):e112-23.
- Defourny N, et al, National costs and resource requirements of external beam radiotherapy: A time-driven activity-based costing model from the ESTRO-HERO project. Radiother Oncol. 2019;138:187-94.
- Defourny N, et al, Critical review and quality-assessment of cost analyses in radiotherapy: How reliable are the data? Radiother Oncol. 2019 Dec;141:14-26.
- Lievens Y, et al; ESTRO–HERO Consortium Collaborators. How public health services pay for radiotherapy in Europe: an ESTRO-HERO analysis of reimbursement. Lancet Oncol. 2020 Jan;21(1):e42-e54
- Yolande Lievens, at al, Value-based radiotherapy: A new chapter of the ESTRO-HERO project, Radiotherapy and Oncology, Volume 160, 2021, Pages 236-239
- Josep M. Borras, at al, Innovation, value and reimbursement in radiation and complex surgical oncology: Time to rethink, Radiotherapy and Oncology, Volume 169, 2022, Pages 114-123Other activities
None declared
Meetings
Meetings
None declared